Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.53 |
| ▸ | TEK | Q02763 | 14/20 | 0.53 |
| ▸ | KIT | P10721 | 13/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067122 | 0.89 | KDR (0.47) | KDRTEKKITLIMK1 | |
| SCHEMBL7070678 | 0.83 | KDR (0.51) | KDRTEKKITAURKA | |
| SCHEMBL7071402 | 0.82 | KDR (0.49) | KDRTEKKIT | |
| SCHEMBL6093276 | 0.80 | KDR (0.52) | KDRTEKKITAURKA | |
| SCHEMBL7074176 | 0.79 | KDR (0.61) | KDRTEKKITLIMK1AURKA | |
| SCHEMBL4479074 | 0.78 | KDR (0.52) | KDRTEKKITAURKA | |
| SCHEMBL6092732 | 0.78 | KDR (0.72) | KDRTEKKITLIMK1AURKA | |
| SCHEMBL7069558 | 0.77 | KDR (0.54) | KDRTEKKIT | |
| SCHEMBL7069598 | 0.76 | KDR (0.51) | KDRTEKKITAURKA | |
| SCHEMBL7071233 | 0.75 | KDR (0.57) | KDRTEKKITAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885TEK 328/4885KIT 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.